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ASSOCIATION OF RIBOFLAVIN, CAFFEINE, AND
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We have used UV and visible spectrophotometry to study self-association of aromatic riboflavin molecules
(RFN, vitamin B2, 7,8-dimethyl-10-N-(1′-D-ribityl)isoalloxazine) in aqueous solution (pH 6.86) at T = 298 K,
using a dimer model. We have determined the equilibrium dimerization constant for riboflavin, KdB = 125 ±
40 M−1. We have studied heteroassociation in the system of molecules of 7,8-dimethyl-10-ribitylisoalloxazine
with 1,3,7-trimethylxanthine (caffeine) and sodium salicylate (NAS) in aqueous solution (pH 6.86; T = 298 K).
We have determined the heteroassociation constants for RFN–NAS and RFN–caffeine molecules in the absence
and in the presence of urea in solutions using a modified Benesi–Hildebrand equation: 25 ± 4, 17 ± 3, and
74 ± 11, 53 ± 7 M−1 respectively. We have determined the dimerization constants for NAS (2.7 ± 0.5 M−1)
and caffeine (17.0 ± 1.5 M−1). We conclude that heteroassociation of the aromatic molecules leads to a lower
effective riboflavin concentration in solution, and the presence of urea in mixed solutions leads to an decrease
in the complexation constants for the RFN–NAS and RFN–caffeine systems.
Key words: spectrophotometry, riboflavin, caffeine, sodium salicylate, urea, self-association, dimer model, heteroas-
sociation, dimerization constant, heteroassociation constant.
Introduction. Effective anti-tumor chemotherapy calls for simultaneous use of two or more cytostatics. Possi-
ble interaction between drugs included in the combination may alter the pharmacokinetic and pharmacodynamic char-
acteristics of the individual components, leading to weakening or conversely enhancement of the anti-tumor effect and
the toxicity [1]. Due to lack of clear understanding of the biochemical and molecular mechanisms of interactions be-
tween drugs used in combination, the synergism of the biological action of chemotherapeutic drugs has not been sat-
isfactorily explained either at the cellular or the molecular level.
We know [2] that molecules of anthracycline antibiotics in the millimolar concentration range exhibit a strong
tendency toward self-association in solution. This is expressed in the formation of dimers and higher order associates,
stabilized as a result of interaction between the aromatic chromophores of the molecules in the aggregates (stacking)
[2]. Such interactions are also observed with heteroassociation of antibiotics with aromatic biologically active com-
pounds in solution, for example with caffeine [3] and riboflavin (RFN, vitamin B2) [4]. It is hypothesized [5] that this
mechanism dominates in the process of degradation of anthracycline antibiotics, in particular doxorubicin, and some
aromatic carcinogens when bound to riboflavin. A protective effect of riboflavin relative to DNA was observed earlier
in [6, 7], expressed in the significantly decreased binding of aromatic mutagens with nucleic acid in the presence of
the vitamin. Furthermore, it was shown that other aromatic compounds such as caffeine can intercept antibiotic and
mutagen molecules by means of heteroassociation and compete with them for DNA binding sites [8].
In this paper, we study the complexation of molecules of organic compounds: riboflavin, sodium salicylate
(NAS, an analog of aspirin), and caffeine in the presence and in the absence of urea, which may enter the human
body as food ingredients and as medicinal drugs. Their biological activity may change considerably when they enter
the cell in combination [9].
Flavin molecules are based on an isoalloxazine ring (Fig. 1a), which is pteridine condensed with a benzene
ring. The flavin structure has four nitrogen hetero atoms, methyl substituents at the 7 and 8 positions of the benzene
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ring, and also a substituent added to the heterocyclic nitrogen atom at the 10 position. For the flavin widely distributed
in nature, riboflavin or ribitylflavin (7,8-dimethyl-10-N-(1′-D-ribityl)isoalloxazine), the latter substituent is the sugar al-
cohol ribitol. This highly hydroxylated substituent is rather labile and plays the role of a linker in formation of coen-
zymes. The chemical structure of riboflavin is highly specific, since even slight modifications of the isoalloxazine ring
and the ribityl residue in the molecule has a strong effect on the catalytic properties of the enzyme, loss of vitamin
activity, or formation of antagonists [10].
Free riboflavin is readily reduced, and its reduced form is readily oxidized again. This property is used in the
biological function of flavin coenzymes in the electron transport chain.
Riboflavin has photochemical activity, is known as a typical 1O2-sensitizing factor [11], and can be used to
inactivate contaminated medical samples such as blood plasma [12, 13]. Riboflavin deficiency causes formation of in-
dividual breaks in the helix of nuclear DNA [14], increases binding of carcinogens to DNA [7], and decreases the glu-
tathione content in the liver [15].
Caffeine (1,3,7-trimethylxanthine), a methylated purine derivative, is in the methylxanthine class. Caffeine
molecules (Fig. 1b) are planar, electrically neutral heterocyclic compounds containing methyl groups at the 1, 3, 7 po-
sitions, oxygen at the 2,6 positions, and four nitrogen hetero atoms. The biological activity of caffeine is exhibited in
its ability to decrease the carcinogenic effects of mutagenic drugs [16]. It has been established that caffeine can be
used as a prophylactic anticarcinogen when there is risk of developing cancer of the digestive tract [17–19], breast
cancer [20, 21], pancreatic cancer [22], and thyroid cancer [23]. According to modern data, an important role in the
mechanism of action for caffeine is played by its inhibiting effect on the enzyme phosphodiesterase, which leads to
intracellular accumulation of cyclic adenosine monophosphate.
Sodium salicylate (NAS), the sodium ester of salicylic acid (Fig 1c), is a nonsteroidal anti-inflammatory drug
containing a carboxyl anion in the 1 position and a hydroxyl group in the 2 position of the benzene ring, which makes
it quite soluble in water. NAS has a pharmacological action similar to that of acetylsalicylic acid (aspirin).
Urea, H2N–CO–NH2 (carbamide, the end product of protein metabolism in vertebrates) is widely used as a
denaturant. In aqueous solutions in concentrations 6–8 M, urea breaks down the tertiary structure of proteins [24]. The
molecular mechanism of action of urea, which is the basis for the change in the natural properties of proteins, is still
unclear [25]. In [26], urea is considered as a "structure breaker" for water, which interferes with the ability of water
molecules to maintain a tetrahedral geometry of the hydrogen bonds and weakens the hydrophobic effect upon asso-
ciation of the molecules.
Fig. 1 Structural formulas for the riboflavin (a), caffeine (b), and sodium sali-
cylate (c) molecules.
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Salicylates of alkali metals, urea, and alkaloids like caffeine, along with their therapeutic properties have hy-
drotropic properties [27, 28], as is apparent in their ability to increase many-fold the solubility of therapeutic drugs [29–
32] including riboflavin [33]. Mechanisms underlying their hydrotropic action include specific interaction with the
solvent, self-association of the hydrotropic agent, and complexation between the hydrotropic and drug molecules [34–36].
The aim of this work was to determine the ability of biologically active NAS and caffeine molecules to form
noncovalent complexes with riboflavin, and the possibility of regulation of the pharmacological activity when they are
used in combination. We have used optical spectrophotometry to study self-association of riboflavin molecules in aque-
ous solution. We studied heteroassociation of the molecular systems RFN–NAS and RFN–caffeine in the absence and
in the presence of urea. Quantitative analysis was performed using the experimental concentration dependences of the
optical density at the wavelength of the riboflavin monomer absorption maximum.
Experimental Procedure. The electronic absorption spectra were recorded on an SF-46 spectrophotometer in
the visible region. In the self-association study, the optical density of the riboflavin solutions were measured in the
wavelength range 340–520 nm. Complexation of mixed solutions of RFN–NAS, RFN–caffeine, RFN–NAS-urea, and
RFN–caffeine-urea were studied in the wavelength range 390–520 nm.
Riboflavin from Serva Feinbiochemica GmbH (Heidelberg, Germany), sodium salicylate, caffeine, and urea
from Sigma (USA) were used with no additional purification. The starting solutions of the studied drugs were obtained
by addition of a weighed amount of the sample in 0.1 M Na phosphate buffer (pH 6.86). Because of their sensitivity
to light (in the blue region of the spectrum), the drugs were weighed and their solutions were prepared in a darkened
room. All the studied solutions were prepared using twice-distilled water immediately before the measurements.
In the self-association study, aqueous solutions of riboflavin in the concentration range 2.5⋅10–3 to 5⋅10–5 M
were obtained by the method of successive dilution. When recording the spectra, we used glass cuvets with optical
path length 10.0, 5.0100, 2.0082, 1.0202, 0.5062, 0.2020, 0.1065, 0.0505, and 0.0207 cm. While recording the spectra,
the temperature inside the cuvet compartment of the spectrophotometer (298 K) was held constant within ±0.25 K by
a thermostat device.
In the heteroassociation study of the systems RFN–NAS and RFN–caffeine, the riboflavin (0.1 M Na phos-
phate buffer, pH 6.86) was titrated by sodium salicylate in the concentration range 2⋅10–4 to 4⋅10–1 M and by caffeine
in the range 8⋅10–4 to 6⋅10–1 M. The riboflavin concentration was held constant in the mixed solutions (CRFN = [B0]
= 5⋅10–5 M = const). The effect of urea on formation of heteroassociates was studied for a constant urea concentration
(1.0 M) in the solutions. The measurements were made in quartz cuvets with optical path length 1.02 cm at constant
temperature T = 298 ± 0.25 K.
Results and Discussion. Self-association of riboflavin. Figure 2 shows the experimental spectra of aqueous so-
lutions of riboflavin (0.1 M Na phosphate buffer, pH 6.86, T = 298 K), measured at riboflavin concentrations in the
range 5⋅10–5 to 2.5⋅10–3 M. As we see, when the riboflavin concentration is increased in aqueous solution, the absor-
bance decreases at the wavelength of the monomer absorption maximum (λmax = 446 nm) and at the same time an
isosbestic point appears at the wavelength λ ≈ 490 nm. The spectral changes and the presence of an isosbestic point
suggest the existence in solution of an equilibrium state between the monomer and dimer forms of the riboflavin mole-
cules.
The dynamic equilibrium in solution was modeled by the scheme [37]:
B1 + B1 <⎯⎯⎯>
KdB
       B2 , (1)
where KdB is the equilibrium dimerization constant of the molecules; B1 and B2 are the monomers and dimers of the
riboflavin molecules. The total concentration of molecules in solution is:
[B0] = [B1] + 2 [B2] , (2)
where [B0] is the initial concentration of the substance; [B1] is the monomer concentration; [B2] = KdB[B1]2 is the
dimer concentration.
The overall molar absorption coefficient ε, provided by the monomer and dimer components of the riboflavin
molecules, can be represented in the form:
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ε = εm fm + εd fd , (3)
where εm, εd are the molar absorption coefficients of the monomers and the riboflavin molecules within the dimer
complexes; fm = [B1]/[B0] is the equilibrium mole fraction of the molecules in monomer form; fd = 2KdB [B1]2/[B0] is
the equilibrium mole fraction of molecules within the dimers. The concentration [B1] is determined from the law of
conservation of mass (2).
The extinction coefficients of the monomer and dimer forms of the riboflavin molecules (εm, εd) and the equi-
librium dimerization constant of the molecules (KdB) are determined as the model parameters:
ε = εd + (εd − εm) 
1 − √⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯1 + 8 [B0] KdB
4KdB [B0]
(4)
from the experimental concentration dependence at the wavelength 446 nm (Fig. 3).
As a result of the calculations, we obtained KdB = 125 ± 40 M–1, εm = (10.8 ± 0.8)⋅103 M–1⋅cm–1, εd = (6.5
± 1.1)⋅103 M–1⋅cm–1. The value of the equilibrium dimerization constant for the riboflavin molecules KdB is probably
determined by the structure of the riboflavin molecule and the experimental conditions.
Fig. 2 Electronic absorption spectra of aqueous solutions of riboflavin (RFN)
(0.1 M Na phosphate buffer, pH 6.86, T = 298 K):  CRFN = 5⋅10−5 (1),
2⋅10−4 (2), 5⋅10−4 (3), 1⋅10−3 (4) and 2.5⋅10−3 (5) M.
Fig. 3 Molar absorption coefficient for an aqueous solution of riboflavin (0.1
M Na phosphate buffer, pH 6.86, T = 298 K) at the wavelength of the ribo-
flavin absorption maximum (λmax = 446 nm) vs. the logarithm of the concen-
tration.
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Heteroassociation of riboflavin and NAS or caffeine. Figure 4 shows the electronic absorption spectra of an
aqueous solution of riboflavin (CRFN = [B0] = 5⋅10–5 M = const) when NAS is added to it at different concentrations
(2⋅10–4–4⋅10–1 M).
In titration of riboflavin by sodium salicylate, we observe changes in the electronic spectrum of riboflavin, ex-
pressed in the hypochromic effect and the bathochromic shift of the absorption bands relative to the maximum of the
flavin monomer band (446 nm), and also in the appearance of isosbestic points at wavelengths of 405 nm and 470
nm. These changes in the absorption spectra of flavin and also the presence of isosbestic points suggest the presence
of specific interactions [38] between the riboflavin and NAS molecules, and formation of heterocomplexes of the in-
teracting molecules in aqueous solution.
Heteroassociation of NAS (caffeine) and riboflavin molecules was analyzed using the Benesi–Hildebrand equa-
tion [39] for the condition [A0] >> [B0], where [A0] is the initial concentration of NAS (caffeine).
The equilibrium in solution was modeled by the scheme [37]:
A1 + B1 <⎯⎯⎯>
K
          A1B1 ,   A1 + A1<⎯⎯⎯>
KdA
       A2 , (5)
where K is the equilibrium heteroassociation constant for the NAS (caffeine) and riboflavin molecules; KdA is the equi-
librium dimerization constant for the NAS (caffeine) molecules; A1 and A2 are the monomers and dimers of the NAS
(caffeine) molecules); A1B1 is the heterocomplex.
The heteroassociation constant for the overall process of formation of the complex is determined by the equation:
K = 
[A1B1]
[A1] ([B0] − [A1B1])
 , (6)
where [A1B1] is the concentration of the heterocomplex; [A1] is the concentration of NAS (caffeine) monomers.
Eliminating the concentration of the complex [A1B1] from formula (6), expressed in terms of its optical den-
sity using the Bouguer–Lambert–Beer law, we obtain:
Dk = 
εkl [B0] K [A1]
K [A1] + 1
 ,
(7)
Fig. 4 Absorption spectra of aqueous solutions of heterocomplexes (0.1 M Na
phosphate buffer, pH 6.86, T = 298 K) of the system riboflavin–sodium sali-
cylate ([RFN] = 5⋅10−5 M = const) for NAS concentrations: 0 (1), 2⋅10−4 (2),
1.5⋅10−3 (3), 1.25⋅10−2 (4), 3⋅10−2 (5), 5⋅10−2 (6), 1⋅10−1 (7), and 2⋅10−1 (8) M.
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where Dk and εk are the optical density and the molar absorption coefficient of the riboflavin molecules within the
heterocomplex at the wavelength corresponding to the absorption maximum of the riboflavin monomers: l is the opti-
cal path length in the solution of the heterocomplex.
Transforming the optical density of the solution D = εml[B1] + εkl[A1B1] for the riboflavin molecules, taking
into account Eq. (7), we obtain the concentration dependence of the overall absorption of the studied molecules:
D = Dm 
∆εl [B0] K [A1]
K [A1] + 1
 , (8)
where Dm is the optical density of the dilute solution containing only riboflavin; [B0] = 5⋅10–5 M; ∆ε = εm – εk; [A1]
= (−1 + √⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯1 + 8KdA[A0]  ) ⁄ 4KdA (the formula for calculating the concentration of NAS (caffeine) monomers) is obtained
from an equation analogous to Eq. (2)).
Expression (8), describing the optical density of the solution, contains three unknown parameters: K, KdA, and
∆ε, determined from the concentration dependences of riboflavin absorption at the wavelength 446 nm (Fig. 5).
Using the modified Benesi–Hildebrand equation (7), we obtained the equilibrium constants for the formation
of RFN–NAS (caffeine) heterocomplexes and dimer complexes of NAS (caffeine) for riboflavin and NAS: K = 25 ±
4 M–1 and KdA = 2.7 ± 0.5 M–1, and for riboflavin and caffeine: K = 74 ± 11 M–1 and KdA = 17 ± 1.5 M–1. The
dimerization and heteroassociation constants vary in the following order: KdA < K < KdB.
The intermediate value of the heteroassociation constant in both the first and the second case (KdA < K <
KdB) is due to the electronic configuration of the complexes formed. We should point out that the heteroassociation
constants of the studied molecular systems take on an intermediate value between the equilibrium self-association con-
stants for caffeine, NAS, and riboflavin, as has also been observed for other molecular systems [40]. The smallest
value of KdA is obtained for the NAS molecules. This is possibly connected with the structure of NAS, containing one
aromatic ring, and with the weak dispersion forces stabilizing the dimer π complexes. The constant KdB is mainly de-
termined by the presence in the riboflavin molecule of a hydrophobic ring system with a large dipole moment, promot-
ing dimerization of the molecules, and a massive ribityl chain, creating steric hindrances in formation of the dimers.
The closeness of the chemical structures of riboflavin and flavin mononucleotide allows us to hypothesize that
the nature of their interaction in self-association and heteroassociation is similar. Like many aromatic dyes and antibi-
otics, flavin mononucleotide molecules form stacked associates as a result of vertical interaction between chromophores
(stacking) [41–44]. Based on the spectrophotometric studies and exciton theory, in [45] the structure parameters of the
flavin mononucleotide dimer in aqueous solution were established and a sandwich (plane-parallel) dimer model was
proposed.
Fig. 5 Concentration dependences of the optical density of aqueous solutions
(0.1 M Na phosphate buffer, pH 6.86; T = 298 K) of the molecular com-
plexes: RFN–caffeine (1); RFN–caffeine–urea (2); RFN–NAS (3); RFN–NAS–
urea (4) ([RFN] = 5⋅10−5 M = const; [urea] = 1.0 M = const) at the
wavelength of the riboflavin absorption maximum (λmax = 446 nm).
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The equilibrium constants for the formation of RFN–NAS and RFN–caffeine heterocomplexes in the presence
of urea in solution are K = 17 ± 3 M–1 and K = 53 ± 7 M–1 respectively, i.e., the stability of the complexes decreases.
Conclusion. We have shown that riboflavin effectively aggregates in solution and also forms complexes with
sodium salicylate and caffeine. Self-associates and heteroassociates of the molecules are predominantly stabilized by
dispersion and hydrophobic interactions between the aromatic chromophores in the complexes. Analysis of the dynamic
equilibrium of the interacting molecules in solution allowed us to conclude that heteroassociation with caffeine and so-
dium salicylate reduces the monomer concentration of riboflavin molecules in solution. The effect of urea on the stud-
ied molecular systems is apparent in the decrease in the binding forces in the heterocomplexes due to weakening of
the hydrophobic effect. Considering that the major biological effect of riboflavin is exhibited in the interaction between
its monomers and molecular receptors of the cell, we can hypothesize that RFN–caffeine and RFN–NAS heteroassocia-
tion should lead to a change in the biological activity of riboflavin in the presence of caffeine and NAS.
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